Esperion Therapeutics, Inc. (NasdaqGM: ESPR)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Esperion Therapeutics, Inc. (NasdaqGM: ESPR) operates in the Pharmaceuticals industry within the Health Care sector.
trading between 1.80 and 4.18.
Tweenvest scores Esperion Therapeutics, Inc. across four factors: quality 37/100, value 58/100, growth 100/100. Its strongest factor is growth.
ESPR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $418.24M
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $4.18
- 52-week low
- $1.80
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 294
- Next earnings
- —
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
- ISIN
- US29664W1053
- Founded
- 2008
- Listed since
- Jun 26, 2013
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.